All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus: A systematic review with meta-analysis and trial sequential analysis

Review (26 RCTs;n=24,348) found insulin did not increase all-cause mortality (RR 0.99; 95%CI 0.92–1.06), cardiovascular mortality (1.01, 0.91–1.13), myocardial infarction (1.02, 0.92–1.15) or stroke (0.87, 0.68–1.12) but did increase risk of severe hypoglycaemia (2.98, 2.47–3.61)

Source:

Diabetes Research and Clinical Practice